Short term
/
Buy
Trade view / 03 May 2017 at 9:53 GMT

Calls on GSK attractive ahead of Advair generic decision — #SaxoStrats

Head of Equity Strategy / Saxo Bank
Denmark
Instrument: GSK:xlon
Price target: 100
Market price: 31
Background

Shares in Danish insulin producer Novo Nordisk are up 7% today as the company's first-quarter results beat revenue and net income estimates and it lifted the lower end of its previous full-year guidance. The big question is whether this is a signal to get on the bandwagon of Novo Nordisk. While the result was definitely good and maybe the turning point for Novo Nordisk, our quant model (Equity Radar) on equities now rates Novo Nordisk the least attractive among the 19 healthcare stocks in the S&P 350 Europe Index (see table below). Momentum is still weak, and the shares have outperformed the industry massively over the past month.

Equity Radar
Equity Rader
Source: Saxo Bank Quantitative Strategies

In the top of the table, the most attractive European healthcare stock is Britain's GlaxoSmithKline. Its shares have been under pressure lately as analysts have downgraded the outlook as a generic alternative to the company's Advair lung drug is on the way. Mylan failed to get US Food and Drug Administration approval for its generic, but next potential approval is Hikma/Vectura with a verdict expected around May 10. If this generic is also rejected by the FDA, it could likely be a short-term catalyst for analyst upgrades as it would give GSK more time to roll out its Advair replacement Breo and less competition to Advair.

The best way to play GSK is through call options over this event as that locks in the downside in case the FDA approves a generic replacement for Advair.

Management and risk description

As we are playing this trading idea through long call options, we are locking in our downside risk. The main risks in this trade are obviously FDA approval of Hikma/Vectura's generic or a stronger GBP which could happen if British prime minister Theresa May gains further in the polls.

GlaxoSmithKline weekly share price
GlaxoSmithKline share price
Source: Saxo Bank 

Parameters


Entry: we are entering the June 16, 2017 calls (44 days to expiry) with a strike at 1,550. The contract size is 1,014 so the total premium paid for one contract is £359.97 before commission and other fees. The premium translates into 2% of the underlying. The current mid price of this call option is £31p compared with the last price at £35.50p.

Trade ticket
 





























Source: Saxo Bank

Stop: As we are playing this through call options, the premium paid is our natural stop loss excluding commission and other fees. The premium is £359.97, translating into around 2% of the underlying, so this is our estimated maximum loss.

Target: Our target is £100-110p on the call option, which, at expiry, translates into an underlying price of around £1,666-1,716p, which is around the highs seen three times the past year (see price chart in the risk management section).

Time horizon: With 44 days to expiry, the time horizon is short.


— Edited by John Acher

Non-independent investment research disclaimer applies. Read more
A compiled overview of Trade Views provided on TradingFloor.com is found here

Disclaimer

The Saxo Bank Group entities each provide execution-only service and access to Tradingfloor.com permitting a person to view and/or use content available on or via the website is not intended to and does not change or expand on this. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Tradingfloor.com and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Bank Group by which access to Tradingfloor.com is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Bank Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Bank Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Tradingfloor.com or as a result of the use of the Tradingfloor.com. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Bank Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. When trading through Tradingfloor.com your contracting Saxo Bank Group entity will be the counterparty to any trading entered into by you. Tradingfloor.com does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of ourtrading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws. Please read our disclaimers:
- Notification on Non-Independent Invetment Research
- Full disclaimer

Check your inbox for a mail from us to fully activate your profile. No mail? Have us re-send your verification mail